Chief Physician, Department of Urologic Oncology, Peking University Medical Doctorate. 2022: Director of the Department of Nephrology (Tibet Aid Mission), Lhasa People's Hospital, Tibet Autonomous Region. 2024: Academic Director, Biotherapy Center, Yunnan Cancer Hospital. Specialty: Comprehensive treatment of renal cancer, bladder cancer, prostate cancer, and melanoma, including chemotherapy, targeted therapy, and immunotherapy. Academic Appointments: Member of the Rare Renal Cancer Collaboration Group, Urogenital and Male Reproductive Tumor Professional Committee, Chinese Anti-Cancer Association; Member of the Tumor Cardiology Expert Committee, Chinese Society of Clinical Oncology (CSCO); Member of the Youth Committee, Oncology Branch, Beijing Medical Association. Representative Achievements: Served as a principal sub-investigator in multiple Phase I-III clinical trials for urologic tumors and melanoma. As a principal sub-investigator, completed pivotal or marketing trials for novel drugs including Toripalimab, Disitamab Vedotin, and Vorolanib. Participated as a principal sub-investigator in global multicenter Phase III studies such as Sacituzumab Govitecan. Published several SCI papers as first author or co-first author in journals including *Annals of Oncology*, *Journal of Clinical Oncology*, *Journal of Hematology & Oncology*, *MED*, and *EBioMedicine*. Led an in-hospital project on combined targeted and immunotherapy for advanced collecting duct carcinoma and a Tibet Autonomous Region natural science project on hypoxia-related pathways and treatment in bladder cancer.